Discussions

Hi everyone! I'm the editor from Hong Kong DengYue Medicine. Today, I'd like to share an exciting topic that's been lighting up the industry—Chinese innovative drugs are rapidly expanding onto the global stage. As a Hong Kong-based pharmaceutical wholesaler specializing in import and export of new, specialty, and rare medicines, we truly believe our core value lies in the relentless pursuit of excellence and innovation, while always prioritizing sustainability and social responsibility. This means building everything on a foundation of quality, compliance, and integrity—actively engaging in global markets to help bring outstanding Chinese-developed therapies to patients worldwide, ultimately contributing to healthier lives for people everywhere.
Let's look at the impressive scorecard from 2025: Chinese biopharma companies signed a record-breaking 157 out-licensing deals totaling around US$136 billion (some reports cite figures like US$135.7 billion or exceeding US$130 billion), more than doubling from the previous year. This surge reflects China's shift from being a follower to a true innovator in global drug development. Standout deals include massive partnerships with international giants—think multi-billion-dollar agreements in oncology, immunology, and metabolic diseases. These collaborations not only bring substantial funding back to Chinese R&D but also earn strong international validation for the quality and potential of our innovations.
What’s driving this boom? Global pharma faces patent cliffs and needs fresh, cutting-edge molecules, while Chinese companies excel in efficient R&D, cost advantages, and high-speed clinical advancements. We've seen a move from simple licensing to more collaborative models like co-development and shared commercialization—true partnerships built on trust and mutual benefit. Oncology remains a hotspot, but we're also seeing breakthroughs in areas like rare diseases, autoimmune conditions, and cardiometabolic therapies.
Looking ahead to 2026, industry experts predict the momentum will continue at a high level, or even accelerate. With clinical data readouts from global multicenter trials expected to drive further deals, and around 20 blockbuster new drugs potentially gaining approvals in China (covering tumors, infections, and more), the focus is shifting from "BD dominance" to "data-driven" progress. This could open even more doors for Chinese innovations to reach patients globally.
At Hong Kong DengYue Medicine, we're proud to play a small but meaningful role in this journey. By upholding the highest standards of quality and ethical practices, we support the smooth flow of these advanced therapies across borders—not just helping bring Chinese excellence to the world, but also contributing to a more sustainable and inclusive global health ecosystem.
What are your thoughts on China's innovative drugs going global in 2026? Do you see particular therapeutic areas leading the charge? Drop your views in the comments—we'd love to hear from you and keep the conversation going for a brighter, healthier future!